GlassScriptPhysician profile
Frank Fang
NPI 1649433368
$4,116.49
in general payments reported to CMS, 2019-2025
22 companies · $272 in 2025
The $272 reported for 2025 was less than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48.87 · 2021: $145 · 2022: $1,272 · 2023: $1,221 · 2024: $1,158 · 2025: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $1,507 · Food and Beverage: $1,143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $1,507.34 |
| Food and Beverage | $1,143.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $1,652.25 | 2021-2024 | Durasorb Monofilament Mesh, Acell |
| Allergan, INC. | $741.21 | 2022 | |
| Abbvie INC. | $333.97 | 2023-2025 | |
| Leo Pharma INC. | $284.51 | 2022-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $199.18 | 2022-2024 | Taltz, Olumiant |
| Sientra, INC. | $175.94 | 2022 | |
| Ucb, INC. | $165.62 | 2024-2025 | Bimzelx |
| Incyte Corporation | $119.68 | 2022-2025 | Opzelura |
| Janssen Biotech, INC. | $71.08 | 2022-2024 | Simponi Aria, Stelara, Simponi |
| Stryker Corporation | $48.87 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $37.40 | 2024 | Dupixent |
| Kyowa Kirin, INC. | $35.68 | 2022 | |
| Genzyme Corporation | $35.19 | 2023 | |
| Next Science LLC | $33.00 | 2024 | Blastx, Xperience, Surgx |
| Ethicon US, LLC | $29.75 | 2024 | Vistaseal, Stratafix |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $25.68 | 2023 | Vtama |
| Solventum Corporation | $23.69 | 2025 | Prevena Restor Bellaform |
| Biofrontera INC. | $23.32 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Amgen INC. | $21.77 | 2023 | Otezla |
| Kci USA, INC. | $20.94 | 2023 | Activ.A.C. |
| Heron Therapeutics, INC. | $20.69 | 2025 | Zynrelef |
| Sanara Medtech INC. | $17.07 | 2023 | Celleraterx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Fang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.